EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (the "Agreement") is entered into as of June 29, 2000 ("Effective Date") by and among ABBOTT LABORATORIES, an Illinois corporation, having a principal place...Exclusive License and Development Agreement • October 16th, 2002 • Rubicon Medical Corp • Surgical & medical instruments & apparatus • Illinois
Contract Type FiledOctober 16th, 2002 Company Industry Jurisdiction
Standard Contracts
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT by and between and Ascletis BioScience Co. Ltd. Dated January 18, 2019Exclusive License and Development Agreement • June 23rd, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations
Contract Type FiledJune 23rd, 2023 Company IndustryTHIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), is executed as of January 18, 2019 by and between 3-V Biosciences, Inc., a corporation organized under the laws of Delaware (“3-V”), having a principal place of business at 3715 Haven Ave. Suite 220, Menlo Park, CA 94025, and Ascletis BioScience Co. Ltd. (also known as 歌礼生物科技(杭州)有限公司), a corporation under the laws of China having a registered office at Room 1102,Building D,198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou, China (“Ascletis”). 3-V and Ascletis are sometimes collectively referred to herein as the “Parties” or individually as a “Party”.
Exclusive License and Development Agreement between Sorrento Therapeutics, Inc. and China Oncology Focus LimitedExclusive License and Development Agreement • November 25th, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
Contract Type FiledNovember 25th, 2014 Company Industry JurisdictionTHIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”) is made and entered into as of this 3rd day of October, 2014 (“Effective Date”) between Sorrento Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America (“USA”) with its principal offices at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 US (“SORRENTO”), and China Oncology Focus Limited, a company organized and existing under the laws of British Virgin Islands with its registered office at Offshore Incorporations Centre, P.O. BOX 957, Road Town, Tortola, British Virgin Islands (“Lee’s”), an Affiliate of Lee’s Pharmaceutical Holdings Limited with a principal offices at Unit 110-111, Bio-Informatics Centre, No. 2 Science Park West Avenue, Hong Kong Science Park, Shatin, Hong Kong.
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • March 26th, 2008 • SafeStitch Medical, Inc. • Blank checks • Illinois
Contract Type FiledMarch 26th, 2008 Company Industry JurisdictionTHIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”) is made as of the 26th day of May 2006, by and between Creighton University (the “University”) and SafeStitch LLC, a Virginia limited liability company (the “Company”). References to an Article, Section, or paragraph mean an Article, Section or paragraph of this Agreement, unless otherwise specified.
ContractExclusive License and Development Agreement • January 31st, 2024 • Kiora Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledJanuary 31st, 2024 Company Industry
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • October 29th, 2013 • Cempra, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 29th, 2013 Company IndustryThis Amendment No. 1 (“Amendment”) to the EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT, dated as of May 8, 2013, by and between CEMPRA PHARMACEUTICALS, INC (“Cempra”) and TOYAMA CHEMICAL CO., LTD. (“Toyama”) is hereby effective as of September 26, 2013. Capitalized terms not defined herein shall have the meaning given to them in the Original Agreement.
AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • November 7th, 2018 • Melinta Therapeutics, Inc. /New/ • Pharmaceutical preparations
Contract Type FiledNovember 7th, 2018 Company IndustryThis Amendment No. 2 (“Amendment No. 2”) to the EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT, dated as of May 8, 2013 and amended as of September 26, 2013, by and between CEMPRA PHARMACEUTICALS, INC. (“Cempra”) and TOYAMA CHEMICAL CO., LTD. (“Toyama”) is hereby effective as of September 12, 2018. Capitalized terms not defined herein shall have the meaning given to them in the Agreement.
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • July 31st, 2013 • Cempra, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 31st, 2013 Company Industry JurisdictionTHIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of May 8, 2013 (the “Effective Date”) by and between CEMPRA PHARMACEUTICALS, INC., a Delaware corporation having an address at Building Four Quadrangle, 6340 Quadrangle Drive, Suite 100, Chapel Hill, North Carolina 27517 USA (“Cempra”), and TOYAMA CHEMICAL CO., LTD., a Japanese corporation having an address at 2-5, Nishishinjuku 3-chome, Shinjuku-ku, Tokyo 160-0023, Japan (“Toyama”). Cempra and Toyama may be referred to herein individually as a “Party” or collectively, as the “Parties.”
FIRST AMENDMENT TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • October 16th, 2002 • Rubicon Medical Corp • Surgical & medical instruments & apparatus
Contract Type FiledOctober 16th, 2002 Company Industry